ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: SU-OR31

Two-Year Results from a Randomized, Controlled Study of Obinutuzumab for Proliferative Lupus Nephritis

Session Information

Category: Glomerular Diseases

  • 1203 Glomerular Diseases: Clinical, Outcomes, and Trials


  • Rovin, Brad H., Ohio State University, Columbus, Ohio, United States
  • Aroca Martinez, Gustavo, Simon Bolivar University y Clinica de la Costa, Barranquilla, Colombia
  • Alvarez, Analia, CEMIC, Buenos Aires, Argentina
  • Fragoso loyo, Hilda Esther, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico
  • Zuta, Adolfina Elizabeth, Instituto de Ginecología y Reproducción, Lima, Peru
  • Furie, Richard, Northwell Health, Great Neck, New York, United States
  • Brunetta, Paul Gardner, Genentech, Inc, South San Francisco, California, United States
  • Schindler, Thomas, F. Hoffmann-La Roche AG, Basel, Switzerland
  • Hassan, Imran, Hoffmann-La Roche Ltd, Mississauga, Ontario, Canada
  • Cascino, Matthew, Genentech, Inc, South San Francisco, California, United States
  • Garg, Jay P., Genentech, Inc, South San Francisco, California, United States
  • Malvar, Ana, Organizacion Maedica de Investigacion, Buenos Aires, Argentina

NOBILITY demonstrated improved renal responses and complete B-cell depletion with the humanized type II anti-CD20 monoclonal antibody obinutuzumab (OBI) compared with placebo (PBO) through 18 months in patients with proliferative lupus nephritis (LN) when added to standard of care therapies. Two-year results from NOBILITY are reported here.


Patients with class III/IV LN received mycophenolate and steroids and were randomized to OBI or PBO. The primary endpoint was complete renal response (CRR) at week 52. Patients were followed through week 104. Secondary endpoints included overall renal response (ORR) and modified CRR (mCRR).


CRR was greater with OBI than PBO at week 52 (35% vs. 23%, P = 0.115), week 76 (40% vs. 18%, P = 0.007), and week 104 (41% vs 23%, P = 0.026; Table). At week 104, OBI patients had greater improvement in eGFR (+6.5 vs. -3.2 mL/min/1.73 m2, P = 0.018), UPCR, anti-dsDNA, C3, and C4. Serious adverse events (OBI 25% vs. PBO 30%), serious infections (8% vs. 18%) and deaths (1 vs. 4) were not increased with OBI.


NOBILITY demonstrated a sustained benefit of OBI through week 104, approximately 18 months after the final OBI infusion. There were no unexpected safety findings. OBI use in LN will be further evaluated in the Phase 3 REGENCY trial.

Table. Week 104 Results
Week 104 EndpointOBI
Difference (80% CI)P Value
CRR41%23%19% (8, 29)0.026
ORR54%29%25% (14, 36)0.005
mCRR56%33%22% (11, 33)0.015
C3 >90 mg/dL76%47%29% (19, 40)0.008
C4 >10 mg/dL95%74%21% (13, 29)0.001
Mean change in eGFR from baseline (mL/min/1.73 m2)+6.5-3.29.7 (1.7, 18)0.018
Mean change in UPCR from baseline-2.3-1.4-0.96 (-1.4, -0.57)0.002

CRR=UPCR <0.5, serum creatinine (SCr) ≤upper limit of normal (ULN) and ≤115% of baseline, <10 red blood cells per high power field (RBCs/HPF), and no RBC casts. ORR = CRR or partial renal response=UPCR <1 (<3 if baseline UPCR ≥3) and ≤50% of baseline, SCr ≤115% of baseline, and ≤50% increase in urinary RBCs (or <10 RBCs/HPF). mCRR = UPCR <0.5, SCr ≤ ULN.